Literature DB >> 2037319

Enhancement of a delayed hypersensitivity reaction to a contact allergen, by the systemic administration of interleukin-2.

Y Zaloom1, L P Walsh, P McCulloch, G Gallagher.   

Abstract

The immunopharmacological effects of interleukin-2 (IL-2) on the sensitization and effector phases of the delayed-type hypersensitivity (DTH) reaction were studied using contact sensitivity to the haptenizing agent dinitrochlorobenzene (DNCB). When administered at the time of priming to DNCB, IL-2 had no effect on the subsequent magnitude of the response. Interleukin-2 was, however, able to increase the magnitude of the response when given at the time of secondary challenge; the degree of change was directly related to the dose of IL-2. The proportions of T cells in the draining lymph node and spleen of IL-2-treated animals decreased by approximately one-third, but there was no alteration to the balance between CD4+ and CD8+ T cells. The results suggest that the increase in DTH observed was due to a pharmacological effect rather than to an increase in T-cell number.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2037319      PMCID: PMC1384382     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  23 in total

1.  Recombinant interleukin-2 directly augments the cytotoxicity of human monocytes.

Authors:  M Malkovský; B Loveland; M North; G L Asherson; L Gao; P Ward; W Fiers
Journal:  Nature       Date:  1987 Jan 15-21       Impact factor: 49.962

2.  Systemic administration of recombinant interleukin 2 stimulates in vivo lymphoid cell proliferation in tissues.

Authors:  S E Ettinghausen; E H Lipford; J J Mulé; S A Rosenberg
Journal:  J Immunol       Date:  1985-08       Impact factor: 5.422

3.  Interleukin-2 reverses deficient cell-mediated immune responses in rheumatoid arthritis.

Authors:  P Emery; G S Panayi; A M Nouri
Journal:  Clin Exp Immunol       Date:  1984-07       Impact factor: 4.330

4.  In vivo administration of purified Jurkat-derived interleukin 2 in mice.

Authors:  J H Donohue; M T Lotze; R J Robb; M Rosenstein; R M Braziel; E S Jaffe; S A Rosenberg
Journal:  Cancer Res       Date:  1984-04       Impact factor: 12.701

5.  Induction of human T lymphocyte motility by interleukin 2.

Authors:  H Kornfeld; J S Berman; D J Beer; D M Center
Journal:  J Immunol       Date:  1985-06       Impact factor: 5.422

6.  Interleukin-2 can prevent and reverse antigen-induced unresponsiveness in cloned human T lymphocytes.

Authors:  G Essery; M Feldmann; J R Lamb
Journal:  Immunology       Date:  1988-07       Impact factor: 7.397

7.  In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2.

Authors:  M T Lotze; Y L Matory; S E Ettinghausen; A A Rayner; S O Sharrow; C A Seipp; M C Custer; S A Rosenberg
Journal:  J Immunol       Date:  1985-10       Impact factor: 5.422

8.  The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.

Authors:  J J Mulé; S Shu; S A Rosenberg
Journal:  J Immunol       Date:  1985-07       Impact factor: 5.422

9.  Two types of mouse helper T cell clone. III. Further differences in lymphokine synthesis between Th1 and Th2 clones revealed by RNA hybridization, functionally monospecific bioassays, and monoclonal antibodies.

Authors:  H M Cherwinski; J H Schumacher; K D Brown; T R Mosmann
Journal:  J Exp Med       Date:  1987-11-01       Impact factor: 14.307

10.  The reconstitution of cell-mediated immunity in the cutaneous lesions of lepromatous leprosy by recombinant interleukin 2.

Authors:  G Kaplan; R Kiessling; S Teklemariam; G Hancock; G Sheftel; C K Job; P Converse; T H Ottenhoff; M Becx-Bleumink; M Dietz
Journal:  J Exp Med       Date:  1989-03-01       Impact factor: 14.307

View more
  5 in total

1.  Lymphokine-activated killer (LAK) cells modulate the effects of IL-2 on a T cell-mediated immune response.

Authors:  P McCulloch; G Gallagher; L P Walsh; Y Zaloom; J Xie
Journal:  Clin Exp Immunol       Date:  1991-09       Impact factor: 4.330

2.  Model for evaluating cross-sensitivity of DNBS with DNCB using hapten-stimulated in vitro interleukin-2 production by murine lymph node cells.

Authors:  B Xu; K Aoyama; T Matsuyama; T Matsushita
Journal:  Bull Environ Contam Toxicol       Date:  1995-12       Impact factor: 2.151

3.  Lymphokine profiles in contact sensitivity induced by dinitrofluorobenzene and tolerance induced by dinitrothiocyanobenzene.

Authors:  L Wei; K M Müller; J H Saurat; C Hauser
Journal:  Arch Dermatol Res       Date:  1993       Impact factor: 3.017

4.  Delayed-type hypersensitivity responses regulate collagen deposition in the lung.

Authors:  R Kimura; H Hu; J Stein-Streilein
Journal:  Immunology       Date:  1992-12       Impact factor: 7.397

Review 5.  Clinical toxicity of interleukin-2.

Authors:  T Vial; J Descotes
Journal:  Drug Saf       Date:  1992 Nov-Dec       Impact factor: 5.606

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.